facebook twitter linkedin

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE
 
Kraków, 26th September 2011 -  Selvita S.A., Poland based integrated drug discovery services provider, announced today signature of an agreement with Evestra GmbH (Germany), a subsidiary of Evestra Inc (USA), for the delivery of a series of drug metabolism, pharmacokinetic (DMPK) and physicochemical studies.
 
The contracted project involves a set up and implementation of drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability, as well as oral bioavailability and pharmacokinetics assays, both in vitro and in vivo, accompanied by gentotoxicity testing.
 
 
We are keen to take advantage of  Selvita’s know-how to support the process of further development of our project. We’re reassured of the competences that Selvita’s team has and high quality of service they deliver. We truly hope this cooperation will provide a value added for Evestra.” – said Klaus Nickisch, Executive Vice President, Chief Scientific Officer, Evestra Inc.
 
We are very glad that we can conduct this project for Evestra. Evestra’s choice to entrust Selvita with their project is not only a nobilitation for us, but also gives our research team a chance to show their potential and capabilities to run complex projects in yet another field of preclinical research” – said Dr Milosz Gruca, Selvita’s Head of Biology Department. 
 

 

Evestra, Inc. is an emerging biopharmaceutical research and development company with a focus on female healthcare product development. Evestra's mission is to improve the health and wellness of women around the world through innovative technologies and commercially viable products focused primarily on gynecological disorders, breast cancer and fertility control. Evestra's facilities are located on the Tx Biomed campus, where drug substance can be manufactured under GMP regulationns.  Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical needs areas of women's health such as endometriosis and hormonal-dependent breast cancer.  The company is also pursuing new compounds for HRT and has established a strong intellectual property position.

Selvita Group is an independent integrated drug discovery provider.  Selvita offers its clients services ranging from computational chemistry, through chemical development to preclinical in vitro research, done in-house. Company’s mission is to serve its clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating the introduction of new drugs to the market. Since 2010, Selvita is the owner of BioCentrum, which provides in vitro preclinical ADMET services, analytical services and  biochemistry services with special focus on protein engineering and antibody development. Selvita' Group laboratories are certified with the Good Laboratory Practice (GLP) certificate, as well as have the accreditation of Polish General Pharmaceutical Inspectorate.

Media contact:

Natalia Pawela
natalia.pawela@selvita.com
+48 12 297 47 31